Cisplatin is the most commonly used chemotherapeutic agent in the treatment of ovarian cancer. One of the mechanisms of resistance of ovarian tumours to cisplatin is increased nucleotide excision repair activity, in particular increased levels of the endonuclease ERCC1. Since 30-40% of ovarian cancers develop resistance to cisplatin after treatment and these tumours are usually incurable, ERCC1 expression is potentially useful as a predictive marker for the effectiveness of cisplatin-based chemotherapy. Using RT-PCR and Northern blotting, we have examined the expression of a 42 bp differentially spliced sequence in exon 1 of the human ERCC1 gene, loss of which has previously been reported to be correlated with higher levels of ERCC1 mRNA in ovarian cancer cell lines. We report here that this alternate transcript is ubiquitous in human tissues and cancer cell lines, is absent in mouse and thus does not appear to be cancer related. Keywords: ERCC1; nucleotide excision repair; ovarian cancer; cisplatin; splicing As well as repairing UV-induced DNA damage, nucleotide excision repair (NER) is involved in the repair of damage caused by bulky chemical adducts, such as platinum-based chemotherapy agents. Indeed one of the mechanisms of resistance of tumours to cisplatin, the most commonly used chemotherapeutic agent, is increased NER activity (Masuda et al., 1988 (Masuda et al., , 1990 Johnson et al., 1994) , in particular increased levels of ERCC1 (Dabholkar et al., 1994; Li et al., 1999) . The 5 0 incision made by the ERCC1-XPF complex is thought to be a rate-limiting step in the NER pathway, as shown by an increase in excision activity in extracts from non-cisplatin-resistant cells after addition of purified ERCC1-XPF protein, compared with no increase in excision activity after addition of ERCC1-XPF to extracts from cisplatin-resistant cells (Ferry et al., 2000) . Supporting evidence for the important role of ERCC1 in cisplatin resistance is shown by the hypersensitivity of ERCC1 mutants to cisplatin (Hoy et al., 1985; Damia et al., 1996) . In all, 30-40% of ovarian cancers develop resistance to cisplatin after treatment and these tumours are usually incurable (McGuire and Ozols, 1998) . The formation and persistence of DNA-platinum adducts in patients has been correlated with response to treatment (Parker et al., 1991) and the potential use of ERCC1 expression as a predictive marker for the effectiveness of cisplatin-based chemotherapy makes it an important area of study. A polymorphism at codon 118 in exon 4 of ERCC1, in which a C is replaced with a T without any change in the polypeptide sequence, has recently been shown to predict survival for cisplatin-treated non-small cell lung cancer patients (Isla et al., 2004; Ryu et al., 2004) and colorectal cancer patients (Stoehlmacher et al., 2004) , with homozygotes for the normal C allele demonstrating significantly better survival rates than those with the T variant on treatment with cisplatin. This may be due to altered ERCC1 mRNA levels in patients with the variant allele.
A 42 bp sequence, thought to contain a binding site for a transcriptional repressor, has been identified in exon 1 of the human ERCC1 gene (Yu et al., 2001) . Loss of this sequence during splicing produces a shorter transcript that was reported to be correlated with higher levels of ERCC1 mRNA in ovarian cancer specimens. The existence of this 42 bp deletion was subsequently confirmed in a second report from the same group (Li et al., 2004) . Using RT-PCR and Northern blotting we have further examined the relationship between this 42 bp sequence and ERCC1 expression in ovarian cancer cell lines, melanoma cell lines and normal tissues.
Northern blotting was performed on RNA extracted from various ovarian tumour cell lines, both cisplatin resistant and cisplatin sensitive (Langdon et al., 1998) , melanoma cell lines and normal human tissues to assess overall ERCC1 mRNA levels ( Figure 1a ). The ERCC1 mRNA levels seen in the ovarian tumour lines we examined are similar to, or slightly higher than, that found in normal ovary tissue. Cisplatin-resistant cell lines, PEO6 and PEO23, show slightly elevated levels of ERCC1 mRNA compared with their cisplatin-sensitive counterparts, PEO1 and PEO14, respectively. Cisplatinresistant cell line, PEA2, shows slightly lower levels of ERCC1 mRNA compared with its cisplatin-sensitive counterpart, PEA1. Heart tissue and the melanoma cell line, WM115, have similarly high levels of ERCC1. Only the C32 melanoma cell line, kidney and muscle tissues have relatively low levels of ERCC1. The difference in ERCC1 expression between PEO23 (the most abundant) and kidney (the least abundant) was threefold.
An RT-PCR assay was carried out on the same RNAs (Figure 1b) . The RT-PCR was designed to amplify the ERCC1 exon 1 to exon 2 region, containing the 42 bp sequence previously identified as a possible regulator of transcription (Yu et al., 2001; Li et al., 2004) . A 206 bp band is seen in all samples, which represents PCR product amplified from the known human ERCC1 cDNA sequence. Another smaller product is observed whose size is consistent with that of a 42 bp deletion from the 206 bp band. It has been suggested that ovarian cancer specimens that express high overall levels of ERCC1 transcripts express the deleted transcript as well as the undeleted transcript, while in specimens expressing low overall levels of ERCC1 transcript, the deleted transcript is absent (Yu et al., 2001) . However, in each of our ovarian cell lines, some of which are cisplatin sensitive, both of these PCR products are present. In each case, the full-length product is present at a higher level than the deleted product.
To determine whether the presence of the deleted mRNA is correlated with overall ERCC1 expression, we also examined a range of human tissues that express various levels of ERCC1 transcript as shown by Northern blotting. All of these tissues produce a deleted RT-PCR product, even ones in which ERCC1 is expressed at lower levels. Indeed all the cell lines and tissues examined express the undeleted and deleted transcripts at similar ratios (1.2-1.6 : 1). These data make it difficult to maintain that the deleted transcript is correlated with high levels of ERCC1 expression, as suggested by Yu et al. (2001) , and therefore its significance remains unclear. In addition, the deleted transcript is clearly present in normal ovary tissue and indeed other tissues, which PEO23 and PEA2 are cisplatin-resistant derivatives of PEO14 and PEA1, respectively. C32 and WM115 are melanoma cell lines. Each blot has one RNA present on one of the other blots to allow comparison between blots. Tissue RNAs were obtained from Stratagene, and all other RNAs were extracted using RNAbee (Biogenesis). Northern analysis was performed as described (Thompson et al., 1989) , using a human ERCC1 cDNA probe excised from an IMAGE clone (HGMP; accession BC008930). Bottom panels show ethidium bromide staining of 18S ribosomal RNA. ERCC1 signal was quantified by phosphorimagery, and 18S ribosomal RNA staining was quantified by densitometry. Expression was calculated as the ratio of ERCC1 signal to 18S ribosomal RNA staining, with the lowest expression value (kidney) set to 1.0. (b) RT-PCR analysis of the same RNAs as in (a). cDNA was made using 5 mg of total RNA, 0.1 mg of random hexamers (Roche) and dNTPs to a concentration of 1.25 mM in a volume of 10 ml. This was denatured at 651C for 5 min and snap-chilled. The reverse transcriptase reaction was then carried out in a volume of 20 ml in a buffer containing 50 mM Tris-HCl pH 8.3, 6 mM MgCl 2 , 40 mM KCl, 1 mM DTT, 20 U of RNAsin (Promega) and 30 U of M-MuLV reverse transcriptase (Roche) for 2 h at 371C. PCR was performed using Taq DNA polymerase (Invitrogen) according to the manufacturer's instructions, with the following thermocycling profiles: ERCC1 exons 1 and 2, 30 cycles (35 for ovary) of 941C for 1 min, 601C for 1 min and 721C for 1 min using primers H-exon1-A (5 0 -CTGGCCGTGCTGGCAGTG-3 0 ) and H-exon 2-3 0 (5 0 -CTCGTCGAGGGGTATCACAAATTTC-3 0 ); HPRT exons 3-9 (accession M31642), 25 cycles of 951C for 30 s, 581C for 30 s and 721C for 30 s using primers HPRT1 (5 0 -CTTGCTGACCTGCTGGGAT-3 0 ) and HPRT2 (5 0 -TCTGGAGTCCTATTGACATCGC-3 0 ). ERCC1 PCR products were 206 and 164 bp; HPRT product was 450 bp. Quantification of ERCC1 RT-PCR bands was achieved by densitometry and expressed as the ratio of signal from the 206 bp band relative to signal from the 164 bp band. The positions of ERCC1 primers in relation to cDNA sequence are shown in the bottom diagram; numbering is relative to ATG initiation codon ( þ 1). TSS, transcription start site indicates that its presence is not related to carcinogenesis in general and ovarian cancer in particular.
To further investigate the nature of the transcript with the 42 bp deletion, we aligned the human and mouse ERCC1 gene sequences to reveal that the human 42-bpdeleted sequence aligns with the first 48 bp of the mouse intron 1 sequence (Figure 2a) . At each end of the human 42-bp-deleted sequence lies a consensus 5 0 splice junction, CAGGT. This would allow the possibility of two alternate splice products in human, depending on which of these 5 0 splice sites is utilized, with a difference of 42 bp. In mouse, the 5 0 end of the sequence ,which aligns with the human 42 bp deletion, also has a consensus 5 0 splice junction, CAGGT. However, the 3 0 end of this sequence is CAGGGT, an extra G disrupting the consensus 5 0 splice junction. Indeed when we carried out similar RT-PCR assays on RNA extracts from several mouse tissues, we found a sole Ercc1 mRNA equivalent to the smaller transcript found in human cells (Figure 2b ). The absence of the larger transcript in rodents is a further indication that alternate splicing of this 42 bp sequence has limited significance.
It has been suggested (Yu et al., 2001; Li et al., 2004) that the function of the deleted sequence may be as a transcriptional regulator, as evidenced by luciferase assays and EMSA studies. However, the authors fail to explain how exclusion of this sequence in an alternative transcript, as observed by RT-PCR, would have any effect on transcription, since the difference is seen at the post-transcriptional level.
In summary, these data show that the two alternate forms of ERCC1 transcript exist in every human cell type examined, irrespective of overall expression levels, and are not related to cancer. In addition, the absence of this extra sequence in mouse Ercc1 transcripts suggests that it has limited significance. , which anneal to exons 1 and 2 of mouse Ercc1, and the following thermocycling profile: 30 cycles of 941C for 1 min, 681C for 1 min and 721C for 1.5 min. PCR product was 203 bp. E13.5, whole mouse embryo at day 13.5; E16.5, whole mouse embryo at day 16.5; Ker, cultured mouse keratinocytes; PF20, cultured mouse embryonic fibroblasts; HM-1, cultured mouse embryonic stem cells. The lower diagram shows positions of primers relative to the ATG initiation codon ( þ 1)
